Altimmune (NASDAQ:ALT - Get Free Report) announced its earnings results on Thursday. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01, Zacks reports. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million.
Altimmune Trading Down 9.9 %
Shares of NASDAQ:ALT traded down $0.66 on Monday, reaching $5.99. The company had a trading volume of 2,626,613 shares, compared to its average volume of 2,252,356. The firm has a market capitalization of $426.04 million, a PE ratio of -3.86 and a beta of 0.19. Altimmune has a 52-week low of $5.28 and a 52-week high of $12.35. The firm's 50 day simple moving average is $6.81 and its 200-day simple moving average is $7.20.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on ALT. HC Wainwright reiterated a "buy" rating and set a $12.00 price objective on shares of Altimmune in a report on Monday. Stifel Nicolaus assumed coverage on shares of Altimmune in a research note on Wednesday, January 8th. They set a "buy" rating and a $18.00 price target for the company. William Blair started coverage on Altimmune in a research note on Friday. They issued a "market perform" rating on the stock. Finally, UBS Group started coverage on Altimmune in a research report on Tuesday, November 12th. They set a "buy" rating and a $26.00 target price for the company. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $20.83.
Read Our Latest Research Report on Altimmune
About Altimmune
(
Get Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Featured Stories
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
